Outcomes from chemoradiotherapy for patients with esophageal cancer

AZ Pantling(Royal Sussex County Hospital), P. C. Hale(Royal Sussex County Hospital), Angus Robinson(Royal Sussex County Hospital), Ravikrishna Mamidanna(Royal Sussex County Hospital), G. Newman(Royal Sussex County Hospital), James Gossage, D.K. Manifold(Royal Sussex County Hospital)
Diseases of the Esophagus
November 12, 2010
10.1111/j.1442-2050.2010.01121.x
Cited by 17

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma
|Nature Genetics|2015|320